Evidence map›Paper›PMID 40688723›Full record

ArticleRespiratory medicine case reports2025

Effectiveness of afatinib after long-term gefitinib treatment for

Ayuka Dai-Shinozaki, Jun Sakakibara-Konishi, Kanako C Hatanaka, Kento Wakabayashi, Naofumi Shinagawa, Yoshihiro Matsuno, Yutaka Hatanaka, Satoshi Konno

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ayuka Dai-ShinozakiDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan.
Jun Sakakibara-KonishiDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan.
Kanako C HatanakaCenter for Development of Advanced Diagnostics, Institute of Health Science Innovation for Medical Care Hokkaido University Hospital, Sapporo, Japan.
Kento WakabayashiDepartment of Respiratory Medicine, KKR Sapporo Medical Center, Sapporo, Japan.
Naofumi ShinagawaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan.
Yoshihiro MatsunoDepartment of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.
Yutaka HatanakaCenter for Development of Advanced Diagnostics, Institute of Health Science Innovation for Medical Care Hokkaido University Hospital, Sapporo, Japan.
Satoshi KonnoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Afatinib, a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), irreversibly inhibits the pan-human epidermal growth factor receptor (HER) family. It is effective in patients with lung cancer with various

Indexed as

AdenocarcinomaAfatinibEGFR L858R/S768INSCLC

Identifiers

PMID40688723
PMCPMC12272827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.